Abstract. Hyaluronan-binding protein 1 (HABP1) is among the molecules known to bind to hyaluronan and is involved in a variety of cellular processes, including cell proliferation and migration. HABP1 has been implicated in the progression of various cancers; however, there have been (to the best of our knowledge) few studies on the expression and function of HABP1 in pancreatic ductal adenocarcinoma (PDAC), a topic that is examined in the present study. Immunohistochemical analysis of HABP1 protein was conducted in archival tissues from 105 patients with PDAC. Furthermore, the functional effect of HABP1 on proliferation, colony formation, and migration in PDAC cells was examined by knockdown of HABP1. It was revealed that HABP1 was overexpressed in 49 (46.2%) out of 105 patients with PDAC. Overall survival was significantly shorter in patients with high HABP1 expression than in those with low HABP1 expression (median survival time of 12.8 months vs. 28.5 months; log-rank test, P=0.004). Knockdown of HABP1 expression in PDAC cells resulted in decreased cell proliferation, colony formation, and cell migration activity. Thus, HABP1 may serve as a prognostic factor in PDAC and may be of use as a novel therapeutic target.

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive neoplasms, ranking fourth among the causes of cancer-related deaths in Western countries and Japan (1,2). Currently, multidisciplinary treatments such as surgery, chemotherapy, and radiotherapy are used to treat pancreatic cancer, but the survival outcome has not been significantly improved. In addition, only a limited number of patients with PDAC may benefit from new treatment modalities, including immune checkpoint inhibitors and precision medicine based on genome-wide molecular alterations. Therefore, it is necessary to seek novel therapeutic strategies based on improved understanding of the biological and molecular mechanisms underlying the aggressive progression of PDAC.

Recently, the focus of cancer research has shifted to the microenvironment surrounding cancer cells. PDAC typically consists of a dense stroma comprising various stromal cells and rich extracellular matrices (ECMs) (3). Hyaluronan (HA), a major component of the ECM, accumulates to high levels in the microenvironment surrounding various cancers, including PDAC, and serves an important role in a variety of cellular processes, including cell invasion, migration, and proliferation (4-10). In addition, low-molecular-weight HA (LMW-HA) has been reported to be more critical for cancer progression in terms of invasion and metastasis compared to high-molecular weight HA (HMW-HA) (11-14). In a previous study by the authors it was shown that the accumulation of LMW-HA is correlated with the motility of PDAC cells (4). HA, a large linear glycosaminoglycan weighing up to approximately 107 Da in its naïve form, is produced by hyaluronan synthase enzymes (HASs) and degraded into smaller fragments by hyaluronidases (HYALs). In another previous study, the authors reported that strong expression of HAS2 (one of the HAS proteins) in PDAC was associated with poor survival after surgery (15). Distinct from HA synthesis, HA degradation is implicated in cancer prognosis. Specifically, the cleavage of large HASs (by HYALs or other enzymes) to yield smaller HA fragments is also accelerated in malignant tumors (4,8,11,14). Notably, in a previous study by the authors, HYAL1 [also referred to as KIAA1199 and as cell migration-inducing protein (CEMIP)] was shown to be overexpressed in PDAC (16).
In the present study, focus was on hyaluronan-binding protein 1 (HABP1), one of the multiple known hyaluronan-binding proteins. HABP1 originally was designated globular head receptor for complement component 1q (gC1qR), based on its characterization as a protein that inhibits C1 activation. Aberrant expression and/or function of HABP1 has been reported in neurodegenerative diseases, impaired glucose tolerance, and cancer (17-26). Notably, HABP1 has been demonstrated to play an important role in cancer initiation and progression (27,28). However, there have been (to the best of our knowledge) few studies on the expression and role of HABP1 in PDAC (25). In the present study, the expression, clinicopathological significance, and biological function of HABP1 in pancreatic cancer were investigated.

Materials and methods

Patient demographics. This retrospective study included samples from 105 consecutive patients (61 men and 44 women) with PDAC who were admitted to the Department of Surgery I, School of Medicine, University of Occupational and Environmental Health (Kitakyushu, Japan) between 1994 and 2014. The inclusion criteria included patients i) aged 33-90 years, ii) without other organ metastasis by preoperative examination, iii) diagnosed as having resectable tumors, and iv) definitively diagnosed with PDAC by postoperative pathology. Exclusion criteria included cases with i) preoperative chemotherapy or radiation therapy, ii) distant metastasis or a second cancer, iii) multiple organ failure, iv) history of drug abuse or v) patients who were pregnant. Within one week before pancreatic surgery, all patients underwent a baseline assessment of white blood cell count and of serum levels of alanine aminotransferase, total bilirubin, albumin carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9). Additional intra- and peri-operative data including tumor diameter, surgery time, blood loss, tumor stage, lymph node (LN) metastasis, and arterial involvement were collected. PDAC tissues had been fixed, processed, sectioned at the time of operation. Patients were staged according to Union for International Cancer Control (UICC) criteria (8th edition) (29).

Immunohistochemistry (IHC). The present study used archival tissues obtained from 105 consecutive patients who underwent surgery at the Department of Surgery I, School of Medicine, University of Occupational and Environmental Health (Kitakyushu, Japan). Tissues were fixed in 10% formalin at room temperature for 24 h and cut to a 2-μm thickness. After formalin fixation, the tissue was paraffin-embedded. Written informed consent was obtained from each patient prior to use of their specimens. The present study was approved by the Ethics Committee of the School of Medicine, University of Occupational and Environmental Health (approval no. H26-118).

Paraffin-embedded sections were dewaxed with xylene and gradually hydrated. Endogenous peroxidase activity had been blocked at room temperature by immersing the sections in 0.3% hydrogen peroxide in methanol for 30 min after antigen retrieval was performed by autoclaving in 10 mM citrate buffer (pH 6.0) for 10 min. Each section was additionally blocked using 10% normal rabbit serum (cat. np.424033; Nichirei Biosciences, Inc.). Each section was incubated in a 1:100 dilution of anti-HABP1 antibody (monoclonal anti-C1QBP antibody produced in mouse; catalog no. WH000708M1; Sigma-Aldrich; Merck KGaA) for 1 day at 4°C, prior to being treated with secondary antibody and biotin-streptavidin complex (424033; Nichirei Corporation) for 60 min each at room temperature. The resultant immunoreactions were visualized with diaminobenzidine (Dako; Agilent Technologies, Inc.) and the sections were counterstained with hematoxylin (Wako Pure Chemical).

As a negative control, immunostaining was performed ~5 times using normal pancreatic tissue 2-5 cm away from the cancer. In addition, since the positive control of the anti-HABP1 antibody used was the duodenum, a second negative control was created by immunostaining the duodenum, using a diluted solution [PBS (pH 7.4) containing 0.1% BSA] excluding the primary antibody. The total score for the IHC reaction was quantified based on a staining intensity grade in combination with a score representing the percentage of positive tumor cells. The first value, the staining intensity grade, was determined as follows: 0 (no staining), 1 (weak staining), 2 (moderate staining), and 3 (strong staining). The second value was determined based on the percentage (0 to 100%) extent of reactivity, which was scored as follows: 0 (no positive tumor cells), 1 (≤10%), 2 (11-49%) and 3 (≥50%) (30). Each case was scored independently by two investigators in a blinded manner. The total score for each section was calculated as the product of the staining grade (value of 0-3) and extent of reactivity (0-3), meaning that the total score ranged from 0-9. Total scores ≤4 were regarded as negative for expression, and the remainder were classified as positive for expression. For example, if the staining intensity was strong (3 points) and the staining area was <10% (1 point), the final score was 3, and the sample was classified as negative for expression.

Cell culture and reagents. PDAC cell lines, PANC-1 (CRL-1469; American Type Culture Collection), and NOR-P1 (TKG 0630; Cell Resource Center for Biomedical Research, Institute of Development, Aging and Cancer, Tohoku University) were used, both of which in our laboratory collection were shown (in the present study) to exhibit strong HABP1 expression. As other PDAC cell lines, the strains ASPC-1, Bx-PC3, Capan-1, CFPAC-1 (ASPC-1; CRL-1682, Bx-PC-3; CRL-1687, Capan-1; HTB-79, and CFPAC-1; CRL-1918; American Type Culture Collection), KP-3 (JCRB0178.0; JRCB Cell Bank), MiaPaca-2 (CRL-1420; American Type Culture Collection), SUIT-2 (JCRB01094; JRCB Cell Bank) and SW-1990 (CRL-2172; American Type Culture Collection) were used due to their weak expression of HABP1. NOR-P1 is a pancreatic ductal adenocarcinoma cell line established by Sato et al (31). NOR-P1 was also used in a previous study (4). Separately, an immortalized cell line derived from human pancreatic duct epithelial (HPDE) cells, was also employed; this cell line was a kind gift from Dr Tsao (University of Toronto, Toronto, Canada). The PDAC cell lines were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% streptomycin and penicillin (all from Life Technologies; Thermo Fisher Scientific, Inc.). HPDE was maintained in HuMedia-KG2 (Kurabo Industries, Ltd.). All cell lines were grown at 37°C in a 5% CO₂ incubator.
siRNA knockdown of HABP1. The small interfering RNA (siRNA) used to target HABP1 (ON-TARGETplus SMARTPool Human HABP1; cat. no. L-011225-01-0005) and the negative control siRNA (ON-TARGETplus Control siRNA non-Targeting siRNA #1; cat. no. D-001810-01-05) were purchased from Horizon; PerkinElmer Inc. HABP1 was used a mixture of four target sequences. The target sequences were as follows (HABP1: 5'-GCG AAA UUA GUG CGG AAA G-3', 5'-CGCAGAACGAGGAGUA-3', 5'-UUUCGU GGUGAGAAGUUA-3' and 5'-GAAGUUAGCCUUAC UCCA-3'). The non-targeting siRNA (negative control) was 5'-UGGGUUUACAGUGCAUAA-3'. NOR-P1 and PANC-1 were transfected with 100 nM siRNA using DharmaFECT 1 Transfection Reagent (Horizon; PerkinElmer, Inc.) according to the manufacturer's instructions at 37°C for 48 h. After 48 h of treatment, the cells were used for further experiments.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was isolated from cultured cells using the RNeasy Mini Kit (Qiagen GmbH) according to the manufacturer's protocol. First-strand cDNA was synthesized from 1.0 μg of total RNA using the SuperScript® VILO cDNA synthesis Kit and Master Mix (Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. Quantitative mRNA expression analysis of HABP1 and a control housekeeping gene (GAPDH, encoding glyceraldehyde phosphate dehydrogenase) was performed using TaqMan® Gene Expression Assays and the StepOnePlus™ Real-Time PCR System (both from Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. The amplification program consisted of 10 min of activation at 95°C, and 40 cycles of melting at 95°C for 15 sec followed by annealing/elongation at 60°C for 2 min. The assay IDs for these genes were as follows: Hs00241825_m1 (HABP1) and Hs02758991_g1 (GAPDH). The following oligonucleotides were used for analyses: HABP1 forward, 5'-CTGCACACCCGAGGAGAC AA-3' and reverse, 5'-CATATAAGGCACCAGTCCAAG-3'; GAPDH forward, 5'-CTCCTCCACCTTTTGGACGCT-3' and reverse, 5'-AGGGGAGTTCGTTGGTGT-3'.

The relative quantification was determined based on the Cq values, obtained from the reactions for target genes and an internal control gene in each sample (32).

Cell proliferation assay. PDAC cells (1.0x10^4/dish) treated with the siRNA targeting HABP1 or with the negative control siRNA were incubated for 1, 3 and 5 days at 37°C; cell counts then were determined using 0.5% trypan blue staining at room temperature for 1 min. The cell number was measured using a LUNA™ automatic cell counter (Logos Biosystems).

Colony formation assay. Following treatment with siRNA, PDAC cells were harvested and counted. Consistent numbers of cells (100 cells/dish) from each group were seeded in dishes. Cells were grown for 14 days and colonies were fixed at room temperature for 30 min, with the addition of 1 mL/well 4% neutral formalin solution and stained with 1% aqueous solution at room temperature for 5 min. The number of colonies on each dish was then counted under a light microscope. A colony was defined was as a group of ≥50 cells that was ≥3 mm in size when stained with crystal violet.

Migration assay. The migratory activity of cells was determined by a Transwell cell migration assay using cell culture inserts equipped with a filter membrane containing 8-μm pores (BD Biosciences). The lower chamber was filled with RPMI-1640 medium containing 10% FBS. The upper chamber was filled with 2.0x10^5 cells (for PANC-1) or 5.0x10^4 cells (for NOR-P1) in RPMI-1640 medium (without FBS). After 24 h of incubation at 37°C, the cells remaining on the upper side of the filters were removed. The cells on the bottom surface of the membrane were stained with hematoxylin and eosin at room temperature for 15 min. and the number of cells that had migrated to the bottom surface of the membrane were counted in five randomly selected fields from each sample using a light microscope (x200 magnification).

Western blot analysis. The cells were harvested and total protein was extracted with PRO-PREP protein extraction solution (iNtRON Biotechnology, Inc.). Total protein was quantified using Pierce™ Microplate BCA Protein Assay Kit (Thermo Fisher Scientific, Inc.). Each lane was mounted with 10 μl of solution adjusted to a total protein of 1 μg. Equal amounts of protein per lane were subjected to electrophoresis on a 12% Mini-PROTEAN Precast Gel (Bio-Rad Laboratories, Inc.) and transferred to a polyvinylidene fluoride (PVDF) membrane (ATTO Corporation). Membranes were blocked for 1 h with 3% bovine serum albumin (BSA; Sigma-Aldrich, Merck KGaA) in TBST buffer (Tris-buffered saline, pH 7.4, containing 0.1% Tween-20) at room temperature. Blocked membranes were then incubated overnight at 4°C with anti-HABP1 antibody at a dilution of 1:200 (mouse monoclonal anti-C1QBP antibody; WH0000708M1; Sigma-Aldrich; Merck KGaA) and anti-β-actin at a dilution of 1:5,000 (mouse monoclonal anti-β-actin; 66009-1-lg; ProteinTech Group, Inc.), followed by incubation for 1 h at room temperature with appropriate HRP-conjugated anti-mouse IgG secondary antibodies (cat. no. SA00001-L; ProteinTech Group, Inc.) at a dilution of 1:4,000. The proteins were visualized using an ECL Western Blotting Detection System (GE Healthcare).

Statistical analysis. Statistical analyses were performed using SPSS statistical software (version 25.0; IBM Corp.). Two-tailed chi-squared tests, Student's t-tests, and Mann-Whitney U tests were used for group comparisons. In the present study, Student's t-test was unpaired. Kaplan-Meier survival curves and log-rank tests were used for survival analysis. Prognostic factors were evaluated by univariate and multivariate analyses using Cox proportional hazard regression models. P<0.05 was considered to indicate a statistically significant difference.

Results

Immunohistochemical analysis and prognostic relevance of HABP1 levels in PDAC. In the present study, pancreatic cancer tissue from 105 patients, of which 44 were women, was assessed. The median age was 69 years (range, 33-90 years). PDAC was localized in the pancreas head in 64 cases and in the pancreas body or tail in 41 cases (Table I). All target patients underwent R0 resection surgeries.

Immunohistochemical analysis was used to determine the expression pattern of HABP1 protein in the PDAC tissue samples. HABP1 expression was negative or only slightly
positive (IHC scores 0-4) in normal pancreata, including ductal cells, acinar cells, and islet cells, whereas HABP1 was highly expressed in some tumor cells. Staining was detected in the membrane and/or cytoplasm of the tumor cells (Fig. 1).

Table I. Comparison of clinicopathological variables between patients with low HABP1 expression and those with high HABP1 expression.

| Characteristics | Low (n=56) | High (n=49) | P-value |
|-----------------|------------|-------------|---------|
| Sex             |            |             | 0.559   |
| Male            | 31         | 30          |         |
| Female          | 25         | 19          |         |
| Age, years      |            |             | 0.104   |
| ≤65             | 16         | 22          |         |
| >65             | 40         | 27          |         |
| Location        |            |             | 0.559   |
| Head            | 34         | 30          |         |
| Body and tail   | 22         | 19          |         |
| Tumor marker    |            |             |         |
| CEA             | 2.6 (1.0-13.6) | 2.8 (1.0-3.7) | 0.565   |
| CA19-9          | 63.8 (0.6-4610) | 149.1 (3.0-3450) | 0.402   |
| UICC T          |            |             | 0.191   |
| 1               | 3          | 3           |         |
| 2               | 7          | 1           |         |
| 3               | 34         | 30          |         |
| 4               | 12         | 15          |         |
| Tumor size (cm) |            |             | 0.009*  |
| 2.6 (0.6-7)     | 3.2 (0.6-8) |             |         |
| UICC N          |            |             | 0.566   |
| 0               | 24         | 16          |         |
| 1               | 25         | 26          |         |
| 2               | 7          | 7           |         |
| UICC M          |            |             | 0.533   |
| 0               | 55         | 49          |         |
| 1               | 1          | 0           |         |
| UICC stage      |            |             | 0.201   |
| I (A+B)         | 7          | 2           |         |
| II (A+B)        | 32         | 26          |         |
| III             | 16         | 21          |         |
| IV              | 1          | 0           |         |
| Vascular invasion |          |             | 0.497   |
| Negative        | 15         | 10          |         |
| Positive        | 41         | 39          |         |
| Perineural invasion |      |             | 0.331   |
| Negative        | 31         | 22          |         |
| Positive        | 25         | 27          |         |
| Histological grade |        |             | 0.509   |
| High            | 4          | 6           |         |
| Low             | 52         | 43          |         |
| Adjuvant chemotherapy |    |             | 0.672   |
| +               | 40         | 32          |         |
| -               | 16         | 16          |         |

*Statistically significant difference. HABP1, hyaluronan-binding protein 1; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; UICC, Union for International Cancer Control; T, tumor; N, node; M, metastasis.
With regard to the 105 PDAC cases, 49 (46.7%) exhibited high HABP1 expression, whereas the remaining 56 (53.3%) exhibited low expression, according to our staining quantification criteria. Clinicopathological data were compared between the high‑HABP1 expression group and low‑HABP1 expression group (Table I). Analysis using Student's t‑tests revealed that tumor size (tumor diameter) was significantly larger in the high‑HABP1 expression group than in the low‑HABP1 expression group [mean and range, 3.2 (0.6‑8) vs. 2.7 (0.6‑7) cm; P=0.00883]. There was no significant difference between the groups in other clinicopathological variables, including age, sex, tumor location, levels of tumor markers, UICC stage, as well as other pathological factors, as determined using analysis of two‑tailed chi‑squared tests, Student's t‑tests, and Mann‑Whitney U tests.

In the present study, the observation period was set to 5 years after surgery. The median survival time was 18.8 months (range, 3 to ≥60 months). The survival between the high‑ and low‑HABP1 expression groups was then compared. The overall survival was significantly shorter in patients with high HABP1 expression (median survival time, 12.8 months) than in patients with low HABP1 expression (median survival time, 28.5 months) (log‑rank test, P<0.001) (Kaplan‑Meier survival curve; Fig. 2). In the present study, numerous patients succumbed to cancer metastasis in the HABP1‑high expression group. In the high expression group, 35 out of 49 cases (71%) were reported as pancreatic cancer‑associated deaths. In contrast, in the HABP1‑low expression group, pancreatic cancer‑related deaths were reported in 28 out of 56 (56%) cases (data not shown).

Prognostic factors were examined using Cox proportional hazard regression models. Multivariate analysis revealed high HABP1 expression (P<0.001), preoperative high CA19‑9 levels (P=0.031), histological grade (high/low) (P=0.046), LN metastasis (P=0.015), and tumor stage (P=0.013) to be significantly associated with poor prognosis (Table II).

Functional analysis of HABP1 in PDAC cell lines. First, the mRNA expression of HABP1 was investigated in a panel of 10 PDAC cell lines. HABP1 mRNA was strongly expressed in 5 (50%) out of 10 PDAC cell lines investigated (compared with the level of expression in a control cell line, HPDE) (Fig. 3A). With regard to the cell lines with strong expression, two (NOR‑P1 and PANC‑1) were used for our subsequent experiments.

siRNA was used to knockdown HABP1 expression in NOR‑P1 and PANC‑1 cells, two of the cell lines with strong HABP1 mRNA expression. RT‑qPCR revealed that transfection with the siRNA targeting HABP1 (siRNA HABP1) resulted in a 97‑99% decrease in HABP1 mRNA levels in these cell lines (Fig. 3B and C). Western blot analysis validated the successful knockdown of HABP1 expression at the protein level (Fig. 3D). The proliferation, colony formation, and migration of NOR‑P1 and PANC‑1 cells with and without knockdown of HABP1 were next examined; these experiments were expected to reveal aspects of the biological functions of HABP1 in pancreatic cancer. First, it was assessed whether HABP1 knockdown affected PDAC cell proliferation. A cell counting assay revealed that the knockdown of HABP1 significantly decreased the proliferation of PDAC cells compared with control cells on both days 3 and 5, using Student's t‑tests.
Next, it was revealed that the number of colonies was significantly decreased in the HABP1-knockdown cells compared with the control cells for both cell lines (NOR‑P1, $P=0.011$; and PANC‑1, $P=0.038$; Fig. 4B). Finally, it was investigated whether HABP1 affects cell migration. The Transwell migration assay

Table II. Univariate and multivariate analysis for factors predicting poor prognosis in patients with PDAC.

| Characteristics                        | Univariate analysis |                |                | Multivariate analysis |                |                |
|----------------------------------------|---------------------|----------------|----------------|-----------------------|----------------|----------------|
|                                        | HR                  | 95% CI         | P-value        | HR                    | 95% CI         | P-value        |
| HABP1 (high/low)                       | 1.995               | 1.537–2.591    | <0.001*        | 0.106                 | 0.048–0.237    | <0.001*        |
| Age                                    | 0.650               | 0.411–1.029    | 0.066          | 1.006                 | 0.980–1.034    | 0.637          |
| Sex (male/female)                      | 1.153               | 0.734–1.798    | 0.529          | 0.890                 | 0.482–1.644    | 0.710          |
| Location (head/other)                  | 1.304               | 0.836–2.035    | 0.242          | 0.635                 | 0.342–1.180    | 0.151          |
| Preoperative CEA                       | 1.039               | 0.997–1.083    | 0.073          | 1.020                 | 0.971–1.070    | 0.433          |
| Preoperative CA 19–9                   | 1.001               | 1.000–1.001    | 0.036*         | 1.001                 | 1.000–1.001    | 0.031*         |
| Histological grade (high/low)          | 1.196               | 0.610–2.345    | 0.602          | 0.358                 | 0.130–0.980    | 0.046*         |
| Tumor size                             | 1.255               | 1.098–1.434    | <0.001*        | 1.165                 | 0.932–1.457    | 0.179          |
| Lymph node metastasis                  | 1.283               | 0.921–1.788    | 0.140          | 0.387                 | 0.573–1.965    | 0.015*         |
| UICC stage (I/II/III/IV)               | 1.320               | 0.943–1.846    | 0.106          | 3.716                 | 1.315–10.497   | 0.013*         |
| Vascular invasion (P/N)                | 1.301               | 0.789–2.145    | 0.320          | 1.084                 | 0.530–2.216    | 0.826          |
| Perinural invasion (P/N)               | 1.353               | 0.872–2.099    | 0.178          | 0.842                 | 0.484–1.572    | 0.649          |
| Adjvant chemotherapy (±)               | 0.984               | 0.746–1.296    | 0.906          | 0.766                 | 0.357–1.642    | 0.493          |

*Statistically significant difference. HABP1, hyaluronan-binding protein 1; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; UICC, Union for International Cancer Control; P, positive; N, negative.

Figure 3. HABP1 mRNA expression in PDAC cell lines and in cell lines in which HABP1 was subjected to siRNA-mediated knockdown. (A) RT-qPCR showing HABP1 mRNA expression in HPDE and 10 PDAC cell lines. The assay was performed twice. (B and C) RT-qPCR showing that transfection with siRNA targeting HABP1 (siRNA HABP1) resulted in over 90% knockdown in both NOR-P1 and PANC-1 cell lines. The assay was performed twice. (D) Western blotting showing decreased HABP1 protein levels in the knockdown groups. The images shown here are derived from a single experiment, for which the blots were processed in parallel. The assay was performed twice. HABP1, hyaluronan-binding protein 1; PDAC, pancreatic ductal adenocarcinoma; siRNA, small interfering RNA; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; HPDE, human pancreatic duct epithelial.

(NOR-P1, $P<0.001$; and PANC-1, $P<0.001$; Fig. 4A). Next, it was revealed that the number of colonies was significantly decreased in the HABP1-knockdown cells compared with the control cells for both cell lines (NOR-P1, $P=0.011$; and PANC-1, $P=0.038$; Fig. 4B). Finally, it was investigated whether HABP1 affects cell migration. The Transwell migration assay
demonstrated that knockdown of HABP1 significantly inhibited the migration of PDAC cells compared with the migratory activity of the control for both cell lines (NOR-P1, P<0.001; and PANC-1, P<0.001; Fig. 4C).

**Discussion**

In the present study, the expression and functional significance of HABP1 in PDAC were investigated. The major findings obtained were as follows: i) HABP1 protein was highly expressed in 49 (46.2%) out of 105 patients with PDAC; ii) the survival of patients with PDAC in which HABP1 was strongly expressed was significantly shorter than in those with lower expression of HABP1; iii) multivariate analysis identified high HABP1 expression as an independent factor predicting poor prognosis; and iv) knockdown of HABP1 in PDAC cells resulted in decreased proliferation, colony formation, and migratory activities. Collectively, these findings suggest that HABP1 may play a role in aggressive forms of PDAC.

HABP1 is a multi-functional glycoprotein ubiquitously expressed in various tissues. This protein has been shown to be involved in a variety of cellular processes, including cell motility, senescence, apoptosis, and autophagy (24). Recently, it was revealed that HABP1 overexpression triggers the induction of senescence in fibroblasts (33). These functions of HABP1 demonstrate the important role of this protein in cancer initiation and progression. In fact, overexpression of HABP1 in HepG2 cells was revealed to lead to enhanced cell survival and tumorigenicity by activating HA-mediated cell survival pathways (27,28). Similarly, exogenous administration of HABP1 protein enhanced the migration and tumor growth of a melanoma cell line (34). However, the functional relevance of HABP1 to PDAC remains unknown. In the present study, it was demonstrated, for the first time (to the best of our knowledge), that siRNA knockdown of HABP1 impaired the proliferation, colony formation, and migration of PDAC cells. These findings suggest that HABP1 is involved in the progression of PDAC, as well as in that of other cancer types.

It was also demonstrated that high HABP1 expression was associated with shorter survival times in patients with PDAC who underwent surgery. Consistent with the results of the present study, it recently was reported that high cytoplasmic (but not nuclear) HABP1 levels were strongly correlated with late tumor stages, arterial involvement, LN metastasis,
CA19-9 levels, and poor overall survival in patients with PDAC (25). It was also revealed, in the present study, that high HABP1 expression, as well as LN metastasis, tumor stage, and CA19-9 levels, were factors indicative of poor prognosis. The present study further suggested that histological grade was also an independent factor indicating poor prognosis. In cell experiments, knockdown of HABP1 suppressed the malignant behaviors (such as the proliferation and migration activities) of PDAC cells. These results support the hypothesis that HABP1 is a prognostic factor for poor outcomes. In the immunohistochemical staining performed as part of this study, none of the 105 tested specimens demonstrated nuclear staining with the anti-HABP1 antibody, in contrast to the results reported by Xie et al (25). This difference most likely reflects the use of distinct antibodies. Nonetheless, the present results as well as those of Xie et al are in agreement with regard to the observation that the accumulation of HABP1 in the cytoplasm is an indicator of a poor prognosis. Since nuclear expression was not invoked as a prognostic factor in the study by Xie et al, it is proposed that the expression level of HABP1 in the cytoplasm is the critical characteristic detected by immunohistochemical staining for this protein. In other cancer types, including gastric, breast, and ovarian cancer, increased HABP1 expression levels were associated with worse patient outcomes (27,29,35-40). These findings suggest that HABP1 may be a promising prognostic marker in patients with PDAC and other cancers.

Regarding the therapeutic implications of the present, it was further inferred that HABP1 may be a promising therapeutic target for PDAC. Notably, high HABP1 expression was associated with improved survival of patients with malignant pleural mesothelioma who had received neoadjuvant or adjuvant chemotherapy (41). This result suggests that high HABP1 expression may serve as a biomarker in predicting the response to chemotherapy. In the present study, however, the association between high HABP1 expression and response to chemotherapy was unclear due to the limited number of patients. Further studies will be required to elucidate the relationship between HABP1 levels and chemosensitivity in PDAC.

The limitations of the present study were as follows. First, the study data lacked data on complications of patients with PDAC. Second, the study was a retrospective, single center study. Third, the study population was limited, rendering it difficult to draw a solid conclusion. Fourth, in our cohort of 105 patients with PDAC, some of the established prognostic factors, including adjuvant chemotherapy, did not demonstrate significant association with prognosis. Fifth, the number of cell experiments was not sufficient for statistical analysis in certain experiments. It is therefore inferred that our results may be biased due to the small sample size and long study period. Further investigations with larger and more-recent samples (for example, using tissue microarrays or data obtained by next-generation sequencing) would be required to confirm the results of the present study.

In conclusion, it was demonstrated that HABP1 accumulates to high levels in PDAC cells, and the expression of this protein is associated with prognosis. It was also determined that HABP1 is involved in the proliferation, colony formation, and migration of PDAC cells in vitro. These findings suggest that HABP1 may play a role in the progression of PDAC.

Acknowledgements

The authors would like to thank Ms Ueda (Department of Surgery I, University of Occupational and Environmental Health, Kitakyushu, Japan) for providing technical assistance.

Funding

The present research was funded by the University of Occupational and Environmental Health.

Availability of data and materials

The data that support the findings of this study are available (in anonymized form) from the corresponding author upon request.

Authors' contributions

YA conducted the molecular studies and drafted the manuscript. NS conceived the study, and participated in its design and coordination, and helped to draft the manuscript. TO, TA, YK SK, and TN participated in the molecular studies. KH participated in the design of the study. YA, NS and KH confirm the authenticity of all the raw data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study received ethical approval from the Ethics Committee of the University of Occupational and Environmental Health (Kitakyushu, Japan; approval no. H26-118). All patients provided written informed consent prior to specimen collection.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394-424, 2018.
2. National Cancer Center Japan: Cancer Registry and Statistics. Cancer Information Service. https://ganjoho.jp/en/index.html; Accessed 1 March, 2022.
3. Michl P and Gress TM: Improving drug delivery to pancreatic cancer: Breaching the stromal fortress by targeting hyaluronic acid. Gut 61: 1377-1379, 2012.
4. Cheng XB, Kohi S, Koga A, Hirata K and Sato N: Hyaluronan stimulates pancreatic cancer cell motility. Oncotarget 7: 4829-4840, 2016.
5. Itano N, Zhuo L and Kimata K: Impact of the hyaluronan-rich tumor microenvironment on cancer initiation and progression. Cancer Sci 99: 1720-1725, 2008.
6. Jacobetz MA, Chan DS, Nesse A, Bapiro TE, Cook N, Frese KK, Fung C, Nakagawa T, Caldwell MF, Zecchini HI, et al: Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 62: 112-120, 2013.
19. Li K, Gao B, Li J, Chen H, Li Y, Wei Y, Gong D, Gao J, Zhang J, D’Souza M and Datta K: A novel glycoprotein that binds to hyaluronan.

20. Li Y, Wan OW, Xie W and Chung KK: p32 regulates mitochondrial morphology and dynamics through Parkin.

21. Liu Y, Leslie PL, Jin A, Itahana K, Graves LM and Zhang Y: p32 heterozygosity protects against age- and diet-induced obesity by increasing energy expenditure.

22. Liu Y, Leslie PL, Jin A, Itahana K, Graves LM and Zhang Y: p32 regulates ER stress and lipid homeostasis by down-regulating GCS1 expression.

23. Muta T, Kang D, Kitajima S, Fujiwara T and Hamasaki N: p32 protein, a splicing factor 2-associated protein, is localized in mitochondrial matrix and is functionally important in maintaining oxidative phosphorylation.

24. Saha P and Datta K: Multi-functional, multicompartmental hyaluronan-binding protein 1 (HABP1/p32/gC1qR): Implication in cancer progression and metastasis.

25. Xie ZB, Yao L, Jin C, Zhang YF and Fu DL: High cytoplasmic HABP1 expression as a predictor of poor survival and late tumor stage in pancreatic ductal adenocarcinoma patients.

26. Yagi M, Uchiumi T, Takazaki S, Okuno B, Nomura M, Yoshida S, Kanaki T and Kang D: p32/gC1qR is indispensable for fetal development and mitochondrial translation: Importance of its RNA-binding ability.

27. Kaul R, Saha P, Saradhi M, Prasad RL, Chatterjee S, Ghosh I, Tyagi RK and Datta K: Overexpression of hyaluronan-binding protein 1 (HABP1/p32/gC1qR) in HepG2 cells leads to increased hyaluronan synthesis and cell proliferation by up-regulation of cyclin D1 in AKT-dependent pathway.

28. Saha P, Ghosh I and Datta K: Increased hyaluronan levels in HABP1/p32/gC1qR overexpressing HepG2 cells inhibit autophagic vacuolation regulating tumor potency.

29. Brierley JD, Gospodarowicz MK and Wittckind C: TNM classification of malignant tumours. 8th edition. John Wiley & Sons, 2017.

30. Wang J, Song Y, Liu T, Shi Q, Zhong Z, Wei W, Huang S and Pang D: Elevated expression of HABP1 is a novel prognostic indicator in triple-negative breast cancers.

31. Sato N, Mizumoto K, Beppu K, Maehara N, Kusumoto M, Nabe T, Morisaki T, Katano M and Tanaka M: Establishment of a new human pancreatic cancer cell line, NOR-P1, with high angiogenic activity and metastatic potential.

32. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔCt) method.

33. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD and Hingorani SR: Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.

34. Prakash M, Kale S, Ghosh I, Kundu GC and Datta K: Increased hyaluronan levels overexpressed in malignant pleural mesothelioma and is associated with increased survival in surgical patients treated with chemotherapy.